By Margarita Snegireva. Northstar Neuroscience’s late-stage trial of its treatment to improve hand and arm function in stroke victims, did not provide any significant benefit over rehabilitation therapy. Its stocks dropped more than 83 percent.
The trial evaluated the Seattle-based company's experimental cortical stimulation device, which is designed to deliver targeted electrical stimulation to the outer surface of the brain.
Northstar, which is based in Seattle, said it would drop efforts to have the therapy approved by regulators. Northstar’s stock, which ended Nasdaq trading on Friday at $8.36, plunged as low as $1.09 before recovering slightly to end the day at $1.37, down 83.6 percent.
The trial results highlighted the hit-or-miss nature of efforts to develop devices that use electrical stimulation or magnetic fields to treat brain and nerve disorders.
Mindful of successes treating conditions as diverse as epilepsy, deafness and chronic pain, device makers have been investing heavily in what James Cavuoto, publisher of Neurotech Reports, forecasts will be a $3.6 billion neurotechnology market this year.
Russia has been developing an energy module on the basis of the megawatt-class nuclear power plant since 2010. The spaceship needs neither sunlight nor solar batteries
There are legitimate authorities in Donetsk and Luhansk republics now, with which Russia can implement the project of the economic integration of the Donbass
Austria does not intend to expel Russian diplomats because of the spy scandal